Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 2/20 | 0.33 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA7 | P43166 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | APLNR | P35414 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7705520 | 0.90 | DGAT1 (0.41) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL1066048 | 0.90 | DGAT1 (0.41) | DGAT1CA2CA12CA14TDP1 | |
| SCHEMBL3294151 | 0.88 | DGAT1 (0.38) | DGAT1TDP1MAOAMAOB | |
| SCHEMBL7802855 | 0.86 | DGAT1 (0.36) | DGAT1MEN1KMT2A | |
| SCHEMBL5027322 | 0.85 | DGAT1 (0.46) | DGAT1TDP1MAOAMAOB | |
| SCHEMBL9196272 | 0.84 | PAOX (0.36) | DGAT1TDP1MAOAMAOBMEN1 | |
| SCHEMBL587833 | 0.84 | PAOX (0.36) | DGAT1TDP1MAOAMAOBMEN1 | |
| SCHEMBL20496960 | 0.84 | PAOX (0.36) | DGAT1TDP1MAOAMAOBMEN1 | |
| SCHEMBL19065775 | 0.84 | DGAT1 (0.44) | DGAT1TDP1 | |
| SCHEMBL3547991 | 0.83 | DGAT1 (0.45) | DGAT1CA2CA12CA14TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970586-B1 | AMINE FUNCTIONAL POLYAMIDES | GENZYME CORP (US) | 2022-12-07 | — | — | EP | disclosed |
| EP-2968231-B1 | ANTIMICROBIAL POLYAMIDE COMPOSITIONS AND MASTITIS TREATMENT | BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC (US) | 2020-07-01 | — | — | EP | disclosed |
| EP-2968231-A1 | ANTIMICROBIAL POLYAMIDE COMPOSITIONS AND MASTITIS TREATMENT | Merial, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| EP-2970586-A1 | AMINE FUNCTIONAL POLYAMIDES | Genzyme Corporation (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014150451-A1 | ANTIMICROBIAL POLYAMIDE COMPOSITIONS AND MASTITIS TREATMENT | MERIAL LIMITED (US) | 2014-09-25 | — | — | WO | disclosed |
| WO-2014150338-A1 | AMINE FUNCTIONAL POLYAMIDES | GENZYME CORPORATION (US) | 2014-09-25 | — | — | WO | disclosed |
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM, LTD. (IL) | 2012-02-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120035140-A1 | CARBAMOYLPHOSPHONATES AS INHIBITORS AND USES THEREOF | MMP9, MMP26, MMP25 | DGAT1 2256/4885CA2 91/4885CA12 307/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.